Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

COR THERAPEUTICS' PLATELET AGGREGATION INHIBITOR

Executive Summary

COR THERAPEUTICS' PLATELET AGGREGATION INHIBITOR is being developed as a stand-alone therapy for acute thrombosis and for use with thrombolytics in acute care settings. The glycoprotein IIb-IIIa antagonist is the lead compound of COR Therapeutics, a two-year-old, privately-held cardiovascular R&D firm based in South San Francisco. COR expects to initiate human clinicals by 1992 for acute thrombosis associated with heart attacks, unstable angina, and stroke. The company's follow-on compound is a vascular growth inhibitor in development to prevent restenosis following arterial unblocking procedures such as coronary angioplasty. The product, "an antagonist to the platelet-derived growth factor receptor," may work by turning off the mechanisms responsible for the over-production of smooth muscle cells, the company explained. Merrell Dow vet Vaughn Kailian joined COR as president and CEO on March 1. Kailian, 45, succeeded co-founder and ex-Robertson Stephens general partner Lee Douglas, who has been named VP-business development. Kailian rose through the ranks at Merrell Dow to president and general manager for Merrell Dow USA prior to the company's merger with Marion Labs in 1989. He has extensive marketing and sales experience at Merrel Dow, both in the U.S. and overseas. Prior to joining COR, Kailian served as Marion Merrell Dow corporate VP of global commercial development. Other top COR management include VP-Operations and Development Robert Swift, PhD, and Nancy Montgomery, who is the acting chief financial officer. Swift spent five years as Genentech's first director of clinical affairs and before that was with Pfizer for eight years. Prior to joining COR, Montgomery was VP of finance and chief financial officer at Applied Biosystems.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS017324

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel